Compare CZWI & GANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CZWI | GANX |
|---|---|---|
| Founded | 1938 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 158.1M | 159.2M |
| IPO Year | N/A | 2021 |
| Metric | CZWI | GANX |
|---|---|---|
| Price | $17.96 | $3.15 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | 28.4K | ★ 2.2M |
| Earning Date | 01-26-2026 | 11-12-2025 |
| Dividend Yield | ★ 2.01% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.29 | N/A |
| Revenue | ★ $58,987,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $11.29 | N/A |
| P/E Ratio | $13.94 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $12.69 | $1.41 |
| 52 Week High | $18.74 | $4.34 |
| Indicator | CZWI | GANX |
|---|---|---|
| Relative Strength Index (RSI) | 55.88 | 49.06 |
| Support Level | $17.98 | $2.90 |
| Resistance Level | $18.49 | $3.45 |
| Average True Range (ATR) | 0.29 | 0.48 |
| MACD | -0.09 | -0.13 |
| Stochastic Oscillator | 16.18 | 46.59 |
Citizens Community Bancorp Inc is a bank holding company that offers traditional community banking services to businesses, Agricultural operators, and consumers, including one-to-four-family residential mortgages. it also offers a variety of loan products including commercial real estate loans, commercial and industrial (C&I) loans, agricultural real estate loans, agricultural operating loans, residential mortgages, home equity lines-of-credit, and consumer loans and offers deposit products through its branches, including demand deposits, various savings and money-market accounts and certificates of deposit. The company's sources of funds are deposits; amortization, prepayments, and maturities of outstanding loans; other short- term investments; and funds provided from operations.
Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. Geographically, the company operates in Switzerland, Spain, the United States, and Australia.